US2018264087A1PendingUtilityA1

Treatment of short bowel syndrome patients with colon-in-continuity

76
Assignee: SHIRE NPS PHARMACEUTICALS INCPriority: Nov 1, 2004Filed: May 16, 2018Published: Sep 20, 2018
Est. expiryNov 1, 2024(expired)· nominal 20-yr term from priority
Inventors:Elizabeth L. SanguinettiThomas B. MarriottJennifer LopansriConsuelo M. Blosch
A61P 1/02A61P 1/00A61B 5/4222A61K 9/0019A61K 38/26
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for treating an adult human patient with short bowel syndrome with colon-in-continuity with remnant small intestine, the method comprising:
 administering to the patient an amount of [Gly2]hGLP-2 that is effective to improve wet weight absorption in the patient by at least 0.75 L/day.   
     
     
         2 . The method of  claim 1 , wherein the [Gly2]hGLP-2 is administered as a once daily dose by subcutaneous injection. 
     
     
         3 . The method of  claim 2 , wherein the [Gly2]hGLP-2 is administered over a period of at least 21 days. 
     
     
         4 . The method of  claim 3 , wherein the once daily dose of [Gly2]hGLP-2 is from 0.03 to 0.15 mg/kg. 
     
     
         5 . The method of  claim 3 , wherein the patient is dependent on parenteral nutrition prior to administration of the [Gly2]hGLP-2. 
     
     
         6 . The method of  claim 5 , wherein the parenteral nutrition is reduced by volume or frequency of administration following administration of the [Gly2]hGLP-2. 
     
     
         7 . The method of  claim 6 , wherein the once daily dose of [Gly2]hGLP-2 is from 0.03 to 0.15 mg/kg. 
     
     
         8 . The method of  claim 3 , wherein the patient exhibited an increase in colonic crypt depth. 
     
     
         9 . A method for treating an adult human patient with short bowel syndrome with colon-in-continuity with remnant small intestine, the method comprising:
 administering to the patient an amount of [Gly2]hGLP-2 that is effective to improve wet weight absorption in the patient by 750 to 1000 g/day.   
     
     
         10 . The method of  claim 9 , wherein the [Gly2]hGLP-2 is administered as a once daily dose by subcutaneous injection. 
     
     
         11 . The method of  claim 10 , wherein the [Gly2]hGLP-2 is administered over a period of at least 21 days. 
     
     
         12 . The method of  claim 11 , wherein the once daily dose of [Gly2]hGLP-2 is from 0.03 to 0.15 mg/kg. 
     
     
         13 . The method of  claim 11  wherein the patient is dependent on parenteral nutrition prior to administration of the [Gly2]hGLP-2. 
     
     
         14 . The method of  claim 13 , wherein the parenteral nutrition is reduced by volume or frequency of administration following administration of the [Gly2]hGLP-2. 
     
     
         15 . The method of  claim 14 , wherein the once daily dose of [Gly2]hGLP-2 is from 0.03 to 0.15 mg/kg. 
     
     
         16 . The method of  claim 11 , wherein the patient exhibited an increase in colonic crypt depth. 
     
     
         17 . A method for treating an adult human patient with short bowel syndrome with colon-in-continuity with remnant small intestine, the method comprising:
 administering to the patient an amount of [Gly2]hGLP-2 that is effective to improve wet weight absorption in the patient by 423 to 1079 g/day.   
     
     
         18 . The method of  claim 17 , wherein the wet weight absorption is improved by 751 to 1079 g/day. 
     
     
         19 . The method of  claim 18 , wherein the [Gly2]hGLP-2 is administered as a once daily dose by subcutaneous injection. 
     
     
         20 . The method of  claim 19 , wherein the [Gly2]hGLP-2 is administered over a period of at least 21 days. 
     
     
         21 . The method of  claim 20 , wherein the once daily dose of [Gly2]hGLP-2 is from 0.03 to 0.15 mg/kg. 
     
     
         22 . The method of  claim 20 , wherein the patient is dependent on parenteral nutrition prior to administration of the [Gly2]hGLP-2. 
     
     
         23 . The method of  claim 22 , wherein the parenteral nutrition is reduced by volume or frequency of administration following administration of the [Gly2]hGLP-2. 
     
     
         24 . The method of  claim 23 , wherein the once daily dose of [Gly2]hGLP-2 is from 0.03 to 0.15 mg/kg. 
     
     
         25 . The method of  claim 20 , wherein the patient exhibited an increase in colonic crypt depth.

Join the waitlist — get patent alerts

Track US2018264087A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.